الفهرس | Only 14 pages are availabe for public view |
Abstract Summary UC is a persistent IBD characterized by a pattern of recurrence and relief. Assessing the activity of the illness and predicting treatment outcomes in UC patients is vital. The evaluation is based on clinical, serological and endoscopic results. Clinical and serological tests, which are non-invasive, inexpensive and easy to use in clinical practice, are usually used to support the relative degree of inflammation and control the progression of the disease, as no particular approach has been proven optimal for measuring disease behavior. Recent studies have shown that endoscopic mucosal healing tests can be used as a disease incidence predictor and main endpoint. In addition, mucosal healing is reported to be linked to ongoing clinical remission, reduced operational need, reduced hospital rates and a lower risk of colon cancer. The Geboes score shows good reproducibility and modest agreement with the endoscopic grading system. UC is characterized by inflammatory cells that cause epithelial cell death or prominent mucosal attack, including granulocytes, macrophages, lymphocytes and plasma cells. NGAL, a glycoprotein of 25 kDa sometimes called LCN2. NGAL is expressed in a variety of cell types, including the gastrointestinal, respiratory and urogenital tract in neutrophil granulocytes, adipocytes and epithelia. It has been shown that it is a bacteriostatic antimicrobial protein that sequester iron. NGAL has also been shown to serve as a growth and differentiation factor and stabilizes MMP-9 proteolytic enzyme. The purpose of this study is to determine the connection between serum NGAL and endoscopic, histopathological and clinical activities of UC |